相关实验视频
Updated: Jul 2, 2025

06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
608
ADSS:一个复合得分来检测阿尔茨海默氏症疾病的疾病进展
Guogen Shan1, Xinlin Lu1, Zhigang Li1
1Department of Biostatistics, University of Florida, Gainesville, FL, USA.
Journal of Alzheimer's disease reports
|February 26, 2024
概括
一个新的阿尔茨海默病 (AD) 综合评分,ADSS,提高了疾病进展的检测. 这种敏感的工具可以减少临床试验中的样本大小,提高药物开发成功率.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 在临床试验中,复合得分对于跟踪阿尔茨海默病 (AD) 进展至关重要.
- 亚得综合评分 (ADCOMS) 是最近lecanemab试验中使用的一个例子.
研究的目的:
- 开发一个改进的复合分数来预测AD的结果变化.
- 提高AD临床试验中结果测量的敏感性.
主要方法:
- 开发了一种新的复合分数,即具有变量选择的AD复合分数 (ADSS).
- 使用基于ADCOMS的统计模型,删除多余的子尺度.
- 在部分最小平方 (PLS) 回归中包含模型选择.
主要成果:
- 新的ADSS结合了7个认知子尺度.
- 与现有的总分数相比,ADSS在检测疾病进展方面表现出更高的灵敏度.
- 这种增强的灵敏度允许在试验设计中采用更小的样本大小.
结论:
- ADSS可以显著提高阿尔茨海默病药物开发的成功率.
- 它对早期疾病进展的高度敏感性使其对阿尔茨海默病试验有价值.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189

